Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? BioPharma DiveWhile many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.OncologyRead full story pharminent June 5, 2026 (Last updated: June 5, 2026) BioPharma Dive While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet. Oncology Read full story Post navigation Previous: Biogen’s salanersen gains FDA breakthrough therapy designation for SMANext: Stakeholders want Makary’s voucher program paused, call for FDA independence Related Stories Pipeline Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models pharminent September 2, 2026 Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026